Oncology Institute, Inc. (TOI): Nasdaq/NYSE listing notice — Oncology Institute receives Nasdaq delisting warning over bid price below $1.00

Oncology Institute, Inc.

Nasdaq notified TOI on Apr 25, 2023 of non-compliance with minimum bid price rule (5450(a)(2)).
Company has 180 calendar days, until Oct 23, 2023, to regain compliance by closing at $1.00+ for 10 consecutive days.
If not compliant by Oct 23, may qualify for an additional 180-day period if meeting other listing standards.
Company may seek stockholder approval for a reverse stock split to cure deficiency.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Oncology Institute, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(2)

Exact text from the filing

April 25, 2023, The Oncology Institute, Inc. (the “Company”) received a written notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is no longer in compliance with Nasdaq Listing Rule 5450(a)(2), because the minimum bid price of the Company’s common stock has been below $1.00 per share for 30 consecutive business days (the “Notice”). The Notice has no immediate effect on the listing or trading of the Company’s common stock or warrants on the Nasdaq Capital Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days, or until Octobe

View on SEC.gov

18 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Oncology Institute, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-013333

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.